---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Long-term morbidity"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Long-term morbidity. Topics: Consequences of abdominal attacks; Cardiovascular, thromboembolic, and autoimmune comorbidity: Swedish population-based cohort; Comorbidity associated with attenuated androgen prophylaxis; Composite venous thromboembolism: reanalysis of the Swedish cohort; 3 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Consequences of abdominal attacks

> “abdominal attacks may lead to unnecessary surgeries or opiate dependence.”

Source: [Henao et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4859422/)

<a id="topic-2.2.1.7-2"></a>

### Cardiovascular, thromboembolic, and autoimmune comorbidity: Swedish population-based cohort

> “Increased risk of cardiovascular disease (odds ratio [OR] 1.83; 95% confidence interval [CI] 1.32–2.54), including arterial (OR 6.74; 95% CI 1.89–24.06) and venous thromboembolic disease (OR 4.20; 95% CI 2.42–7.23) as well as hypertension (OR 1.64; 95% CI 1.12–2.39) was seen in HAE.”
> “Furthermore, the risk of autoimmune disease was increased (OR 1.65; 95% CI 1.15–2.35) being particularly pronounced for systemic lupus erythematosus (OR 71.87; 95% CI 8.80–586.7).”
> “In contrast, the risk of cancer was not increased.”
> “A two-fold higher prevalence of allergy, asthma, and atopic dermatitis was found (OR 2.19; 95% CI 1.60–2.99).”

Source: [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/)

<a id="topic-2.2.1.7-3"></a>

### Comorbidity associated with attenuated androgen prophylaxis

> “Side effects of attenuated androgens can contribute to comorbidities in HAE since long-term use of danazol is associated with increases in atherogenic indices.”

Source: [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/)

<a id="topic-2.2.1.7-4"></a>

### Composite venous thromboembolism: reanalysis of the Swedish cohort

> “Our analysis revealed that individuals with HAE had a significantly increased risk of composite VTE compared to controls (odds ratio 3.57, 95% confidence interval 2.16-5.81, Figure 1A).”
> “In contrast, individuals with HAE did not have a significantly increased risk of composite ATE (odds ratio 1.3, 95% confidence interval 0.81-2.09, Figure 2B).”
> “C1INH is a potent inhibitor of plasma kallikrein, which spans the kallikrein kinin pathway and intrinsic coagulation pathway, and the intrinsic coagulation pathway components activated factor XII and activated factor XI”

Source: [Grover et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12541594/)

<a id="topic-2.2.1.7-5"></a>

### Comorbidity compared with the general US population: US patient registry

> “Females with HAE-C1INH had a significant increase in the prevalence of depression, sleep disorders, kidney disease, anemia, and hepatitis.”
> “Cardiovascular comorbidities were significantly reduced in the HAE-C1INH group.”

Source: [Christiansen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37619776/)

<a id="topic-2.2.1.7-6"></a>

### Consequences of delayed diagnosis

> “Delays in HAE diagnosis can lead to serious consequences, including reduced quality of life (QoL), loss of productivity and income, depression, unnecessary medical interventions, increased healthcare costs, and an imminent risk of death.”
> “Unnecessary abdominal surgeries, such as appendectomies, along with exploratory diagnostic procedures such as colonoscopy, also are frequent.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.7-7"></a>

### Presumptive post-traumatic stress disorder: US HAE Association survey

> “Participants ≥ 18 with HAE-C1INH were recruited from the US HAE Association: Cohort 1, self-referred; Cohort 2, randomized from the HAEA membership.”
> “The prevalence of presumptive PTSD based on the PLC-C outcomes was between 20 and 25% in HAE-C1INH participants (n = 77).”
> “Diagnosis was correlated with high rates of depression and reduced SF-36 mental domain performance.”

Source: [Christiansen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13488251/)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
